Abstract
Clinically relevant imetelstat concentrations significantly inhibit CFU-MEG formation from MNCs of ET patients and reduce hTERT expression.
However, similar concentrations of imetelstat do not inhibit cytokine-induced CFU-MEG from MNCs of healthy donors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Alleles
-
Amino Acid Substitution
-
Biomarkers
-
Cell Differentiation / drug effects*
-
Enzyme Inhibitors / pharmacology*
-
Female
-
Humans
-
Janus Kinase 2 / genetics
-
Male
-
Megakaryocyte Progenitor Cells / cytology
-
Megakaryocyte Progenitor Cells / drug effects*
-
Megakaryocyte Progenitor Cells / metabolism*
-
Megakaryocytes / cytology
-
Megakaryocytes / drug effects
-
Megakaryocytes / metabolism
-
Middle Aged
-
Mutation
-
Oligonucleotides / pharmacology*
-
Thrombocythemia, Essential / drug therapy
-
Thrombocythemia, Essential / etiology
-
Thrombocythemia, Essential / metabolism*
Substances
-
Biomarkers
-
Enzyme Inhibitors
-
Oligonucleotides
-
JAK2 protein, human
-
Janus Kinase 2
-
imetelstat